Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Certified IRBs to Review How Monitoring/Audits Will Be Conducted for “Specified Clinical Research”: Official
April 10, 2017
- MHLW to Mull Use of Data from “Specified Clinical Research” for Drug Review: Official
April 10, 2017
- Clinical Research Bill Passed into Law
April 7, 2017
- Ex-Min. Tamura’s Study Group Boots Up with Backing of 17 Healthcare-Related Organizations
April 7, 2017
- Domestic Drug Production Logs 1st Rise in 4 Years: 2015 MHLW Survey
April 6, 2017
- Rare Symposium Planned after Closed-Door Regulatory Head Confab in October
April 6, 2017
- AMED Inks Collaboration Pact with Spanish Authority
April 6, 2017
- “I Don’t Use Biosimilars,” Says Ex-Chief of Japan College of Rheumatology
April 5, 2017
- MHLW Releases “Blue Book” Generic Data List
April 4, 2017
- MHLW Sets Up Office for Startup Support, Starts Receiving Applications for Consultations
April 4, 2017
- MHLW Issues Optimal Use Guidelines for Repatha, Praluent
April 3, 2017
- MHLW to Launch Conditional Early Approval for Medical Devices Too
April 3, 2017
- Cabinet Presents Reform of Drug Discovery Support Network Including Use of CROs, Transfer of Drug Makers’ Employees
April 3, 2017
- Avigan Might Be Used for Pandemic Influenza if Existing NA Inhibitors Are Ineffective: Expert Council
April 3, 2017
- CEFP Kicks Off Discussions on Economic and Fiscal Policy Blueprint for 2017
March 31, 2017
- Members of New Counterfeits Panel Call for Eliminating Cash-and-Carry Dealers
March 31, 2017
- Clinical Research Bill Likely to Clear Diet Early April
March 31, 2017
- MHLW Approves Ninlaro, Intuniv, Other Drugs
March 31, 2017
- MHLW to Set up New Council to Discuss Safety Measures for Pharmacotherapy in the Elderly
March 31, 2017
- Drug Price Survey Sheets to Be Distributed with No Prefectural Govts In-Between: Chuikyo
March 30, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…